ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.66454
-0.21%
Brent Oil
82.845
1.06%
Bitcoin
69,328.48
1.19%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vera Therapeutics Inc (VERA)

  7. Vera Therapeutics Inc (VERA) Noticias

VERA

Vera Therapeutics (VERA)

Vera Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VERA
FechaHoraFuenteTítuloSímboloCompañía
17/05/202416:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VERAVera Therapeutics Inc
17/05/202415:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VERAVera Therapeutics Inc
11/04/202406:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:VERAVera Therapeutics Inc
14/02/202415:10Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VERAVera Therapeutics Inc
30/01/202415:52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VERAVera Therapeutics Inc
29/01/202420:58Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:VERAVera Therapeutics Inc
29/01/202415:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VERAVera Therapeutics Inc
08/01/202407:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VERAVera Therapeutics Inc
10/08/202315:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VERAVera Therapeutics Inc
23/06/202315:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VERAVera Therapeutics Inc
22/06/202315:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:VERAVera Therapeutics Inc
20/06/202306:51Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VERAVera Therapeutics Inc
11/05/202315:41Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:VERAVera Therapeutics Inc
13/04/202315:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:VERAVera Therapeutics Inc
30/03/202315:25Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:VERAVera Therapeutics Inc
30/03/202315:24Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:VERAVera Therapeutics Inc
28/03/202315:34Edgar (US Regulatory)Annual Report (10-k)NASDAQ:VERAVera Therapeutics Inc
16/02/202315:07Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:VERAVera Therapeutics Inc
14/02/202316:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:VERAVera Therapeutics Inc
06/02/202315:05GlobeNewswire Inc.Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common StockNASDAQ:VERAVera Therapeutics Inc
01/02/202320:51GlobeNewswire Inc.Vera Therapeutics Announces Pricing of Public Offering of Class A Common StockNASDAQ:VERAVera Therapeutics Inc
01/02/202315:10Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:VERAVera Therapeutics Inc
01/02/202315:01GlobeNewswire Inc.Vera Therapeutics Announces Commencement of Public Offering of Class A Common StockNASDAQ:VERAVera Therapeutics Inc
21/11/202209:15TipRanksH.C. Wainwright Reaffirms Their Buy Rating on Vera Therapeutics (VERA)NASDAQ:VERAVera Therapeutics Inc
18/11/202206:05TipRanksVera Therapeutics (VERA) Receives a Buy from J.P. MorganNASDAQ:VERAVera Therapeutics Inc
22/08/202205:30TipRanksAnalysts’ Top Healthcare Picks: Vera Therapeutics (VERA), ADC Therapeutics (ADCT)NASDAQ:VERAVera Therapeutics Inc
06/07/202206:30GlobeNewswire Inc.Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyNASDAQ:VERAVera Therapeutics Inc
04/06/202213:30GlobeNewswire Inc.Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant PatientsNASDAQ:VERAVera Therapeutics Inc
03/06/202215:13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:VERAVera Therapeutics Inc
20/05/202215:05GlobeNewswire Inc.Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association CongressNASDAQ:VERAVera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VERA

Su Consulta Reciente

LSE
79BO
Morocco 31a
NASDAQ
INMB
INmune Bio
AMEX
XDAT
Franklin Exponential Data
AQEU
HHC
H&H International AS
BMF
TF7Z99
DGFX
MRXUSDT
Metrix
NASDAQ
PCCMX
PIMCO Short Duration Mun...
COIN
ARTXUSD
ARTX Token
NASDAQ
HSIDX
Hartford Schroders Susta...
BIT
I08648
Intesa Sanpaolo
NASDAQ
AFRM
Affirm
EU
P549S
P549S
EU
Y867S
Y867S
NASDAQ
GRPANX
RetirePilot Moderate 203...
USOTC
ZHEIF
Zhou Hei Ya (PK)
LSE
RUC2
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados